SCHEMBL13627968

SCHEMBL13627968

O=C1/C(=N\O)c2cc(Cl)ccc2N1Cc1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 1/20 0.49
PKM P14618 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH2 P05091 1/20 0.47
ALDH3A1 P30838 1/20 0.47
ADRA1D P25100 1/20 0.45
CYP1A2 P05177 1/20 0.44
UCHL3 P15374 1/20 0.44
UCHL1 P09936 1/20 0.44
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA4 P22748 1/20 0.43
KDR P35968 1/20 0.42
LMNA P02545 1/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
AGTR1 P30556 1/20 0.41
GRM5 P41594 3/20 0.41
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627927 0.83 ALDH3A1 (0.68) ALDH1A1PKMALDH2ALDH3A1UCHL3
SCHEMBL13628003 0.81 MEN1 (0.46) ALDH1A1MEN1PKMKMT2AADRA1D
SCHEMBL13627874 0.80 ALDH3A1 (0.56) ALDH1A1MEN1KMT2AALDH2ALDH3A1
SCHEMBL13627875 0.78 UCHL3 (0.53) ALDH1A1ALDH2ALDH3A1UCHL3UCHL1
SCHEMBL13627934 0.78 UCHL3 (0.50) ALDH1A1ALDH2ALDH3A1UCHL3UCHL1
SCHEMBL916908 0.77 ALDH1A1 (0.52) ALDH1A1MEN1PKMKMT2AADRA1D
SCHEMBL916909 0.77 ALDH1A1 (0.52) ALDH1A1MEN1PKMKMT2AADRA1D
SCHEMBL13910749 0.76 ALDH1A1 (0.58) ALDH1A1PKMALDH2ALDH3A1UCHL3
SCHEMBL13627928 0.76 ALDH3A1 (0.51) ALDH1A1ALDH2ALDH3A1UCHL3UCHL1
SCHEMBL13627931 0.76 CA1 (0.56) ALDH1A1MEN1KMT2AALDH2ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ALDH1A1 4310/4885MEN1 4320/4885PKM 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.